Mesoblast (MESO) Cost of Revenue (2015 - 2023)

Mesoblast has disclosed Cost of Revenue across 9 years of filings, most recently posting -$334.2 million for Q2 2023.

• Cost of Revenue for Q2 2023 came in at -$334.2 million, down 10.14% year-over-year; the trailing twelve-month figure through Jun 2023 was $129.1 million (up 20.93% YoY), and the FY2025 annual result was $5.1 million, changed N/A from the prior year.
• Cost of Revenue came in at -$334.2 million for Q2 2023 at Mesoblast, down from $123.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $252.3 million in Q3 2022 to a low of -$339.7 million in Q2 2021.
• The 5-year median for Cost of Revenue is $69.0 million (2019), against an average of $2.2 million.
• Across the five-year window, Cost of Revenue sank 8231.21% in 2020 and surged 2748.37% in 2021, its largest moves.
• Mesoblast's Cost of Revenue stood at $86.3 million in 2019, then slumped by 92.53% to $6.4 million in 2020, then soared by 2748.37% to $183.7 million in 2021, then sank by 52.31% to $87.6 million in 2022, then plunged by 481.46% to -$334.2 million in 2023.
• The last three Cost of Revenue figures came in at -$334.2 million (Q2 2023), $123.4 million (Q1 2023), and $87.6 million (Q4 2022), per Business Quant data.